Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verorab 4-site ID PEP Regimen
NCT01622062Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2012
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rabies virus inactivated antigen, A in rabies (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of participants with seroconversion at Day 14. Started Jun 2012; status: completed.
02
Drugs
rabies virus inactivated antigen, A
03
Conditions
rabies
Beyond the preview
Go deeper on NCT01622062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622062.